methyl 1-((1-methyl-4-oxo-3-(2-(trifluoromethyl)biphenyl-4-ylcarbamoyl)-1,4-dihydroquinolin-7-yl)methyl)azetidine-3-carboxylate | 1372633-66-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 1-((1-methyl-4-oxo-3-(2-(trifluoromethyl)biphenyl-4-ylcarbamoyl)-1,4-dihydroquinolin-7-yl)methyl)azetidine-3-carboxylate
• CAS: 1372633-66-3
• 化学式: C₃₀H₂₆F₃N₃O₄
• 分子量: 549.549
• InChiKey: NNPSUGPBPFJYRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.08
• 重原子数：
  40.0
• 可旋转键数：
  6.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  80.64
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  methyl 1-((1-methyl-4-oxo-3-(2-(trifluoromethyl)biphenyl-4-ylcarbamoyl)-1,4-dihydroquinolin-7-yl)methyl)azetidine-3-carboxylate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以0.026 g的产率得到1-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-4-biphenylyl)carbamoyl)-1,4-dihydro-7-quinolinyl)methyl)-3-azetidinecarboxylic acid
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b
• 作为产物：
  描述：

  7-溴-4-羟基喹啉-3-甲酸乙酯 在 sodium periodate 、 四氧化锇 、 二(三叔丁基膦)钯 、 lithium hydroxide monohydrate 、 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 、 三乙胺 、 cesium fluoride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 58.0h， 生成 methyl 1-((1-methyl-4-oxo-3-(2-(trifluoromethyl)biphenyl-4-ylcarbamoyl)-1,4-dihydroquinolin-7-yl)methyl)azetidine-3-carboxylate
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b